Why the study?
Do age, body size, and CYP2C9 genotype predict warfarin dose requirements in patients on stable long-term therapy?
Do age, body size, and CYP2C9 genotype predict warfarin dose requirements in patients on stable long-term therapy?
Age and CYP2C9 polymorphism significantly affect warfarin dose requirements in patients receiving long-term therapy with stable anticoagulation control.
No takes yet. Share an insight, caveat, or question.
Age and CYP2C9 genotype were associated with warfarin dose; leaves open whether incorporating them improves dosing algorithms in prospective trials.
Kamali et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: